Phase 4
Completed N=90
PrEP at a Syringe Services Program
Source: ClinicalTrials.gov NCT04782180 ↗Enrolled (actual)
90
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcomePrimary: Intracellular Level of Tenofovir Diphosphate Levels Via Dried Blood Spot at 6-month Follow-up — NA fmol/punch
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of this study is to see if providing participants with pre-exposure prophylaxis (PrEP) medicine right away at the IDEA Exchange will help participants remain in HIV negative.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Intracellular Level of Tenofovir Diphosphate Levels Via Dried Blood Spot at 6-month Follow-up |
NA | — |
| SECONDARY Time to PrEP Initiation Post Negative HIV Rapid Test |
— | — |
Eligibility Criteria
Inclusion Criteria
- over the age of 18
- speak either English or Spanish
- ability to provide informed consent
- currently enrolled in the syringe services program
- have a negative HIV rapid test result
- estimated creatinine clearance > 30 ml/minute
Exclusion Criteria
- do not meet the above criteria of inclusion
- decline to participate
- test positive for HIV via rapid test
- are pregnant or plan on becoming pregnant
- have symptoms acute HIV.
- Any other comorbidities that at the discretion of the investigator would prevent the participant from participating in the study.
Data sourced from ClinicalTrials.gov (NCT04782180). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.